Loading
A phase 1/2 trial of CAPOX, Sintilimab, Tislelizumab in oesophageal cancer, run by AskGene Pharma, Inc., active and no longer recruiting.
ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer. is a phase 1/2 interventional study registered as NCT05632939 by AskGene Pharma, Inc., with 62 participants enrolled, started 2023-02-21 and due to reach its primary completion in 2025-10-31. Interventions recorded: ASKB589 +CAPOX+Sintilimab/Tislelizumab. Conditions listed: Gastric Cancer, Gastroesophageal Cancer (GC). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/